A Masked, Randomized, Prospective Study of QLS-111-FDC in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Status: Recruiting
Location: See location...
Intervention Type: Combination product, Drug
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY
Firecrest study is evaluating the intraocular pressure (IOP)-lowering effect, safety, and tolerability of Qlaris' preservative free \[PF\], fixed-dose combination \[FDC\] investigational product (IP) in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 12
Healthy Volunteers: f
View:
• BCVA 1.0 logMAR or better in each eye (equivalent to 20/200)
• Diagnosis of mild to moderate OAG or OHT in at least one eye
• IOP ≥19 mmHg at 08:00 hour (H) at Qualification Visits following a run-in with PF latanoprost
Locations
United States
Florida
Shettle Eye Research
RECRUITING
Largo
Contact Information
Primary
Lisa Brandano
lbrandano@qlaris.bio
9789302103
Backup
Lauryl Hargreaves
lhargreaves@qlaris.bio
Time Frame
Start Date: 2026-03-18
Estimated Completion Date: 2026-07-15
Participants
Target number of participants: 60
Treatments
Experimental: QLS-111-FDC ophthalmic solution
QLS-111-FDC, PF FDC
Active_comparator: Latanoprost ophthalmic solution
PF latanoprost 0.005%
Related Therapeutic Areas
Sponsors
Leads: Qlaris Bio, Inc.